Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

Johnson & Johnson JNJ announced that the FDA approved its precision therapy, Akeega (niraparib and abiraterone acetate ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The ICMR has funded the IPIROC study to evaluate a cost-effective dosing strategy for PARP inhibitor rucaparib in ovarian cancer patients, aiming to enhance access and reduce side effects.

A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.

Meta-analysis shows PARP inhibitors as maintenance therapy improve progression free survival in newly diagnosed advanced ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

Niraparib approved for all-comers whose tumors responded to chemotherapy Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency. The FDA restricted ...

Cancer cells with a cell nucleus that is easily deformed are more sensitive to drugs that damage DNA. These are the findings ...

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...